Devises / AKRO
AKRO: Akero Therapeutics Inc
46.73
USD
0.21
(0.45%)
Le taux de change de AKRO a changé de -0.45% aujourd'hui. Au cours de la journée, l'instrument a été échangé à un minimum de 46.02 et à un maximum de 47.34.
Suivez la dynamique Akero Therapeutics Inc. Les cotations en temps réel vous aideront à réagir rapidement aux changements du marché. En basculant entre différentes périodes, vous pouvez surveiller les tendances et la dynamique des taux de change par minutes, heures, jours, semaines et mois. Utilisez ces informations pour prévoir les changements du marché et prendre des décisions de trading éclairées.
- M5
- M15
- M30
- H1
- H4
- D1
- W1
- MN
AKRO Nouvelles
- Has Akero Therapeutics (AKRO) Outpaced Other Medical Stocks This Year?
- Does Akero Therapeutics (AKRO) Have the Potential to Rally 59.14% as Wall Street Analysts Expect?
- RCKT Stock Rises as FDA Lifts Clinical Hold on Danon Disease Study
- Akero Therapeutics: Reversing My Contrarian Buy Rating To A Contrarian Sell Rating (AKRO)
- Allogene's Q2 Loss Narrower Than Expected, Pipeline in Focus
- Akero Therapeutics CEO Cheng sells $1.46 million in stock
- Akero Therapeutics COO Young sells $597k in shares
- Akero therapeutics director Henderson sells $142k in shares
- Are Medical Stocks Lagging Akero Therapeutics (AKRO) This Year?
- Akero Therapeutics stock strengthened as Morgan Stanley reiterates Overweight rating
- Janus Henderson Global Life Sciences Diversified ADR Managed Account Q2 2025 Commentary
- Akero Therapeutics stock initiated with Buy rating at TD Cowen on MASH potential
- Akero Therapeutics stock initiated with Buy rating at TD Cowen on MASH treatment potential
- This AeroVironment Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Akero Therapeutics (NASDAQ:AKRO), Apartment Inv & Mgmt (NYSE:AIV)
- Janus Henderson Global Life Sciences Fund Q2 2025 Commentary (Mutual Fund:JAGLX)
- Altimmune Gears Up to Report Q2 Earnings: Here's What to Expect
- Amarin Gears Up to Report Q2 Earnings: Here's What to Expect
- Incyte Gears Up to Report Q2 Earnings: Is a Beat in the Cards?
- VKTX Stock Down on Wider-Than-Expected Loss in Q2, Nil Sales
- Altimmune: Potential Tough Road Ahead Amid Fierce Competition (Rating Downgrade) (ALT)
- Exelixis' Q2 Earnings: Will Cabometyx Sales Drive Growth?
- Viking Therapeutics Gears Up for Q2 Earnings: Here's What to Expect
- RCKT Stock Up on FDA's RMAT Tag to Gene Therapy for Heart Failure
- FDA Advisory Panel Votes Against Approval of GSK's Blenrep Combo
Range quotidien
46.02
47.34
Range Annuel
21.34
58.40
- Clôture Précédente
- 46.94
- Ouverture
- 47.01
- Bid
- 46.73
- Ask
- 47.03
- Plus Bas
- 46.02
- Plus Haut
- 47.34
- Volume
- 1.002 K
- Changement quotidien
- -0.45%
- Changement Mensuel
- -3.49%
- Changement à 6 Mois
- -2.65%
- Changement Annuel
- 73.14%
31 août, dimanche